A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis

This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Docetaxel Chemotherapy Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Samsung Medical Center

Seoul, 135-710, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with breast cancer receiving adjuvant/neoadjuvant docetaxel chemotherapy

Exclusion criteria

Patients with breast cancer receiving palliative docetaxel chemotherapy
Patients having onycholysis before docetaxel treatment

Treatment and study plan

EVONAIL® solution

Drug

Other names: Hydrating Nail Solution

Primary outcomes

The incidence of onycholysis Gr 2 or more

Time frame: 12weeks

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2016
First posted: Feb 2, 2016
Registry last updated: Apr 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed